Fig. 3
AurA and CXCL12 promote glioblastoma cell survival, radio-resistance, self-renewal, and proliferation. a Plating efficiency of U87MG and GBM1 cells clonogenic assays after Alisertib (48 h; 0, 10, 25 nM) and CXCL12 (16 h; 0, 100 nM) treatments (n = 4). b Survival fraction after RT of U87MG and GBM1 cells clonogenic assays after Alisertib (0, 10, 25 nM) and CXCL12 (0, 100 nM) treatments (n = 4). Pictures show the survival fractions of U87MG cells for each condition. Scale bars = 10 μm. c Quantification of spheroids of U87MG and GBM1 cells after treatment with Alisertib (25 nM) and CXCL12 (100 nM) (n = 3). Pictures show spheroids formation from U87MG cells for each condition. Scale bars = 50 μm. d Immunofluorescent staining and normalized percentage of Ki-67/Hoechst double-positive U87MG cells 48 h after 5, 10, and 25 nM Alisertib treatment. Pictures show Ki-67 (red) and Hoechst (blue) staining of U87MG cells treated with 0 or 25 nM of Alisertib (20×) Scale bars = 10 μm (n = 3). Graphs are mean values ± SD and are representative of three independent experiments, *p < 0.05, **p < 0.01, ***p < 0.001 (1-way ANOVA and 2-way ANOVA corrected by post-tests if appropriate)
